Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:3/2/2015)... -- According to statistics released by the American Society of ... fillers, such as the JUVEDERM ® family of fillers ... between 2013 to 2014, HA filler treatments increased by 8 ... which shows U.S. unit sales of HA dermal fillers were ... "These findings are consistent with what I see every day ...
(Date:3/2/2015)... , March 2, 2015 Cardinal Health today ... a leading global manufacturer of cardiology and endovascular devices, ... net of the present value of tax benefits. The ... of $1.0 billion in new senior unsecured notes and ... to close in the United States ...
(Date:3/2/2015)... and BETHESDA, Md. , March ... company focused on treating and preventing autoimmune diseases, announced ... monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... agreement, Celimmune has the rights to develop, manufacture and ... Japan . Concurrently, Amgen has been granted ...
Breaking Medicine Technology:Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 2Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 4Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 5Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 6Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 7Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... 2015 To help healthcare ... their practices compliantly and profitably, MDreferralPRO and ... The interoperability between a strategic referral ... practice management system is necessary for a ... A referral management and development solution relies ...
(Date:3/1/2015)... As residents and business owners ... Burns and Carita Weaver, believe in supporting local ... the Southlake Chamber of Commerce, Carroll Independent School ... launched a website for Southlake mayoral candidate Laura ... tool for Hill’s campaign, the website combines images, ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... ... Company, a leading supplier of industrial and technical parts and free CAD images ... input from their customers. John Carrier, the company,s President, says the new ReidSupply.com ... and a de-emphasis on marketing. The new site takes the customer exactly where ...
... during a Caesarean section helps manage pain after the ... Cochrane Researchers. The researchers recommend local anaesthetics as part ... provided that consideration is given to the cost. ... the growing number of women giving birth by Caesarean ...
... , LOS ANGELES, July 7 /PRNewswire-USNewswire/ -- A ... upcoming "Be a Hero for Babies Day" to raise funds ... moms have full-term pregnancies and healthy babies. , , Make a ... and the gift will double in value thanks to ...
... for U.S. research dollars, NIH says , MONDAY, July ... guidelines Monday describing which embryonic stem cell lines will ... of stem cells that can be used for research. ... that embryonic stem cells used in research were obtained ...
... Laboratories, a national clinical and anatomic pathology reference laboratory ... announced today the appointment of Sherrie L. Perkins, MD, ... laboratories, effective, July 1, 2009. , , Dr. ... R. Ashwood, MD, who will be transitioning into the ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
Cached Medicine News:Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Farmers Insurance Pledges to Match All Donations Up to $250k For "Be a Hero for Babies Day" to Benefit March Of Dimes 2Health News:Final Rules Broaden Pool for Stem Cell Research 2Health News:Final Rules Broaden Pool for Stem Cell Research 3Health News:Final Rules Broaden Pool for Stem Cell Research 4Health News:ARUP Laboratories Announces New CMO Appointment 2
... OTI's new Spectral system is a combination ... Laser Ophthalmoscope (SLO) system that provides suberb, ... choroidal-retina structure. With the advancements of spectral ... of up to 27,000 A-Scans per second ...
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
The KMedic Jet Wire Twister is designed to provide fast, smooth and even twisting of soft wire, saving time in the O.R. Now available for the first time in stainless steel. Suitable for the entire ra...
Osteophyte periosteal elevator for bone removing....
Medicine Products: